ASRA Pain Medicine welcomes support from its corporate partners. There are several ways for corporations to be recognized for their support of the organization and its goals. Together, we can make a difference for patients and the education of physicians who serve them. Acceptance of any form of corporate support is independent of ASRA Pain Medicine's policies and programming, and does not constitute endorsement of any company or product.
or contact Elizabeth Smith, Executive Director at firstname.lastname@example.org.
Your best opportunity to partner with ASRA Pain Medicine is through the Corporate Partnership Program. By becoming an ASRA Pain Medicine Corporate Partner, you will help advance the quality of care provided by ASRA Pain Medicine physician member by contributing your voice and support to members' efforts in research, education, treatment, and advocacy. Learn more about the many benefits of becoming an ASRA Pain Medicine Corporate Partner.
Thank You to ASRA Pain Medicine's Corporate Partners:
Pacira BioSciences, Inc. is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Pajunk is headquartered in Geisingen, Germany, with subsidiaries in Atlanta (USA) and Newcastle (UK). In the US, Pajunk specializes in regional anesthesia and pain management by offering market-leading solutions for peripheral and continuous nerve blocks, neuraxial procedures and diagnostics, and interventional pain. Learn more at www.pajunkusa.com or www.pajunk.com.
Information on advertising and sponsorship can be found here.